ZURICH (Reuters) – Germany could only allow coronavirus antibody tests to help determine how freely people can move once it has advice from its ethics council, Health Minister Jens Spahn said, after securing millions of the tests from Swiss drugmaker Roche. Ge... More »
ZURICH (Reuters) – Roche’s experimental drug gantenerumab failed to slow cognitive decline in people with a rare inherited form of Alzheimer’s disease, the latest setback for companies hunting for a cure for the devastating brain-wasting disease. The study foc... More »
ZURICH (Reuters) – Roche (ROG.S) entered into a $1.15 billion licensing agreement with Sarepta Therapeutics (SRPT.O) to obtain the right to launch and commercialize Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United... More »
ZURICH (Reuters) – Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval ... More »
ZURICH (Reuters) – Roche’s Tecentriq immunotherapy mixed with the older cancer drug Avastin lifted both overall survival and progression-free survival in people with liver cancer that cannot be surgically removed, the Swiss drugmaker said on Monday. The compan... More »
(Reuters) – Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year. Roche’s drug and Bayer/Lilly’s Vi... More »
ZURICH (Reuters) – Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world’s biggest maker of cancer drugs pushes ahead in personalized medicines that require a biomarker test to identify prospective patients. Roche said Japan is the ... More »
ZURICH (Reuters) – Swiss drugmaker Roche’s $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition. Roche s... More »
ZURICH (Reuters) – European drugmakers Roche, Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for n... More »
ZURICH (Reuters) – Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer. The com... More »
CHICAGO (Reuters) – In a disappointment for Roche Holding AG (ROG.S), two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials presented on Saturday. Ad... More »
LONDON (Reuters) – Roche’s new hemophilia drug Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position. Hemlibra cut by 96 percent ... More »
ZURICH (Reuters) – Roche’s immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday. Roche ... More »
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann (Reuters) – Swiss drugmaker Roche Holding AG (ROG.S) said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health ... More »
Logo of Swiss drugmaker Roche is seen beside the entrance of its research unit Roche Glycart AG in Schlieren, Switzerland December 18, 2017. REUTERS/Arnd Wiegmann (Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could ... More »
The chairman of Swiss pharmaceutical company Roche, Christoph Franz speaks to media after the annual general meeting in Basel March 4, 2014. REUTERS/Ruben Sprich ZURICH (Reuters) – Fears U.S. President Donald Trump could damage the drugs industry have not been... More »
The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel, January 30, 2014. To match special report USA-FDA/CASES REUTERS/Ruben Sprich/File Photo ZURICH (Reuters) – The European Union approved Roche’s multiple sclerosis medici... More »
FILE PHOTO: The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel, Switzerland, January 30, 2014. REUTERS/Ruben Sprich/File Photo (Reuters) – Swiss drugmaker Roche (ROG.S) will buy U.S. cancer drugmaker Ignyta Inc (RXDX.O) ... More »
FILE PHOTO: The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel, Switzerland, January 30, 2014. REUTERS/Ruben Sprich/File Photo ZURICH (Reuters) – Roche’s patent dispute with London-listed Shire over the Swiss drugmaker’s... More »
Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann ZURICH (Reuters) – Scientists at Swiss drugmaker Roche said on Friday they may have discovered why some tumors resist new immunotherapy dru... More »
FILE PHOTO: The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel, Switzerland, January 30, 2014. REUTERS/Ruben Sprich/File Photo ZURICH (Reuters) – Adding Roche’s (ROG.S) immunotherapy Tecentriq to older drugs doubled the ... More »
FILE PHOTO: FILE PHOTO: Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) – Roche announced a double dose of trial wins on Monday, saying its immunotherapy Tecen... More »
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday. More »
Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said. More »
Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. More »
Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. More »
A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumor, potentially helping to predict which patients may respond best to some immunotherapies. More »
FILE PHOTO: Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann/File Photo Roche’s bid to muscle in on Shire’s share of the $11 billion hemophilia drug market took a new, contentious turn thi... More »
CEO of Shire, Dr Flemming Ornskov, poses for a photograph in London, Britain, July 3, 2017. REUTERS/Peter Nicholls – RTS19MDH Pharmaceutical group Shire (SHP.L) said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche (ROG... More »
Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann Roche is convinced a new breast cancer drug will have a significant role in treating the disease despite recent trial results that disappoi... More »
The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel, January 30, 2014. REUTERS/Ruben Sprich/File Photo A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an oft... More »
Four capules of Tamiflu are pictured on a Tamiflu box in Burbank, California, January 31, 2013. REUTERS/Fred Prouser The first generic copy of Roche’s top-selling flu pill Tamiflu hit the U.S. market on Monday, marking a further step in the Swiss drugmaker’s e... More »
Roche tablets are seen in this photo illustration shot January 18, 2016. REUTERS/Dado Ruvic/File Photo The spotlight on finding a cancer cure has spurred improvements in systems to collect and analyze oncology data, but efforts to track patients with other dis... More »
Roche tablets are seen in this photo illustration shot in Zenica, Bosnia and Herzegovina, January 18, 2016. REUTERS/Dado Ruvic/File Photo Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, ... More »
Team Sky rider Nicolas Roche of Ireland warms up in front of his hotel before a team training session in Zeist, Netherlands, July 2, 2015. REUTERS/Benoit Tessier Bradley Wiggins’ therapeutic use exemption which allowed him to use an otherwise banned drug was e... More »
The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday. More »
Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann Swiss drugmaker Roche (ROG.S) said on Monday the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization (EUA) fo... More »
LONDON Roche has no plans to sell its diabetes testing business, despite a pummeling in the past three years from U.S. price cuts, and the Swiss drugmaker expects the unit to return to sales growth in 2017. Roland Diggelmann, head of Roche diagnostics, said th... More »
ZURICH Roche Holding AG said on Monday the U.S. Food and Drug Administration has granted priority review for atezolizumab for treating people with a specific type of lung cancer. The designation covers treatment of patients with locally advanced or metastatic ... More »
VIENNA Swiss drugmaker Roche Holding has dropped out of a high-profile project to develop an antibiotic for treating “superbug” infections, the company said on Sunday. Roche had agreed in 2013 to pay privately held partner Polyphor up to 500 million Swiss fran... More »
Switzerland’s Roche has a potential new multi-billion-dollar drug to help it diversify beyond cancer treatments following the success of ocrelizumab against a hard-to-treat type of multiple sclerosis. The injectable antibody medicine is the first product to sh... More »
